Penile Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Penile Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Penile cancer is a rare malignancy that develops on the skin or tissues of the penis. It occurs when normal cells in the penis undergo genetic mutations, leading to uncontrolled growth and the formation of a cancerous tumor. Early stages of penile cancer might not cause noticeable symptoms. As the disease progresses, signs and symptoms may include changes in skin color or texture of the penis; persistent growths or sores on the penis; redness, irritation, or ulceration on the penile skin; and pain, bleeding, discharge, or foul-smelling discharge from the penis.
The Penile Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Penile Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Penile Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Penile Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 47 molecules, with 47 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Penile Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Penile Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Penile Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Adagene Suzhou LtdAscendis Pharma AS
AstraZeneca Plc
Beijing Health Guard Biotechnology Inc
BioNTech SE
Bristol-Myers Squibb Co
CanWell Pharma Inc
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
eTheRNA Immunotherapies NV
Exelixis Inc
F. Hoffmann-La Roche Ltd
Gene Surgery
Gilead Sciences Inc
GSK plc
Guangzhou BeBetter Medicine Technology Co Ltd
Hengrui Yuanzheng Biotechnology Co Ltd
Incyte Corp
ISA Pharmaceuticals BV
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Marengo Therapeutics Inc
Merck & Co Inc
Merck KGaA
Merus NV
Nykode Therapeutics ASA
PDS Biotechnology Corp
Precigen Inc
Privo Technologies Inc
Regeneron Pharmaceuticals Inc
Shanghai Bovax Biotechnology Co Ltd
Shanghai De Novo Pharmatech Co Ltd
SQZ Biotechnologies Co
Systimmune Inc
Transcenta Holding Ltd
Transgene SA
Virion Therapeutics LLC
Xencor Inc
Xilio Therapeutics Inc
Y-Biologics Inc
Zhejiang Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Penile Cancer reports